Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Johnson and Johnson
AstraZeneca
Harvard Business School
Colorcon

Last Updated: September 25, 2022

TRILIPIX Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Trilipix patents expire, and when can generic versions of Trilipix launch?

Trilipix is a drug marketed by Abbvie and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has nineteen patent family members in eleven countries.

The generic ingredient in TRILIPIX is choline fenofibrate. There are one hundred and two drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the choline fenofibrate profile page.

DrugPatentWatch® Generic Entry Outlook for Trilipix

There are two Paragraph IV patent challenges for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for TRILIPIX
Drug patent expirations by year for TRILIPIX
Drug Prices for TRILIPIX

See drug prices for TRILIPIX

Drug Sales Revenue Trends for TRILIPIX

See drug sales revenues for TRILIPIX

Recent Clinical Trials for TRILIPIX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Medical University of South CarolinaPhase 4
Chong Kun Dang PharmaceuticalPhase 1
The Scripps Research InstitutePhase 2

See all TRILIPIX clinical trials

Pharmacology for TRILIPIX
Paragraph IV (Patent) Challenges for TRILIPIX
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
TRILIPIX Delayed-release Capsules choline fenofibrate 45 mg 022224 1 2009-09-02
TRILIPIX Delayed-release Capsules choline fenofibrate 135 mg 022224 1 2009-09-01

US Patents and Regulatory Information for TRILIPIX

TRILIPIX is protected by one US patents.

Patents protecting TRILIPIX

Salts of fenofibric acid and pharmaceutical formulations thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie TRILIPIX choline fenofibrate CAPSULE, DELAYED RELEASE;ORAL 022224-001 Dec 15, 2008 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Abbvie TRILIPIX choline fenofibrate CAPSULE, DELAYED RELEASE;ORAL 022224-002 Dec 15, 2008 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for TRILIPIX

When does loss-of-exclusivity occur for TRILIPIX?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 03290060
Estimated Expiration: See Plans and Pricing

Patent: 10249244
Estimated Expiration: See Plans and Pricing

Austria

Patent: 9777
Estimated Expiration: See Plans and Pricing

Canada

Patent: 10261
Estimated Expiration: See Plans and Pricing

China

Patent: 26024
Estimated Expiration: See Plans and Pricing

Patent: 0473378
Estimated Expiration: See Plans and Pricing

Patent: 1480384
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 72190
Estimated Expiration: See Plans and Pricing

Patent: 29541
Estimated Expiration: See Plans and Pricing

Patent: 32285
Estimated Expiration: See Plans and Pricing

Germany

Patent: 313359
Estimated Expiration: See Plans and Pricing

Japan

Patent: 06511541
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 05005736
Estimated Expiration: See Plans and Pricing

Russian Federation

Patent: 56549
Estimated Expiration: See Plans and Pricing

Patent: 00398
Estimated Expiration: See Plans and Pricing

Patent: 05122439
Estimated Expiration: See Plans and Pricing

Patent: 08149770
Estimated Expiration: See Plans and Pricing

Spain

Patent: 86486
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRILIPIX around the world.

Country Patent Number Title Estimated Expiration
Canada 2510261 FORMULATION COMPORTANT DE L'ACIDE FENOFIBRIQUE, UN SEL OU UNDERIVE PHYSIOLOGIQUEMENT ACCEPTABLE DE CET ACIDE (FORMULATION COMPRISING FENOFIBRIC ACID, A PHYSIOLOGICALLY ACCEPTABLE SALT OR DERIVATIVE THEREOF) See Plans and Pricing
European Patent Office 1829541 Formulation comprenant de l'acide fénofibrique ou l'un de ses sels physiologiquement acceptable (Formulation comprising fenofibric acid or a physiologically acceptable salt thereof) See Plans and Pricing
China 1726024 Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof See Plans and Pricing
Spain 2286486 See Plans and Pricing
Japan 2006511541 See Plans and Pricing
European Patent Office 1832285 Formulation comprenant de l'acide fénofibrique ou l'un de ses sels physiologiquement acceptable (Formulation comprising fenofibric acid or a physiologically acceptable salt thereof) See Plans and Pricing
Russian Federation 2005122439 КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ ФЕНОФИБРИНОВУЮ КИСЛОТУ, ЕЕ ФИЗИОЛОГИЧЕСКИ ПРИЕМЛЕМУЮ СОЛЬ ИЛИ ПРОИЗВОДНОЕ See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for TRILIPIX

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1746976 LUC00026 Luxembourg See Plans and Pricing PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT, SUCH AS IRINOTECAN SUCROSOFATE SALT IN A PEGYLATED LIPOSOME, SUCH AS A LIPOSOME COMPRISING 1,2-DISTEAROYL-SN-PHOSPHATIDYLCHOLINE, CHOLESTEROL AND N-(OMEGA-METHOXY-POLY(ETHYLENE GLYCOL) (MOLECULAR WEIGHT 2000)-OXYCARBONYL)-1,2-DISTEAROYLPHOSPHATIDYL ETHANOLAMINE, E.G. IN THE MOLAR RATIO 3:2:0.015; AUTHORISATION NUMBER AND DATE: EU/1/16/1130 20161018
1746976 CA 2017 00030 Denmark See Plans and Pricing PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT, SUCH AS IRINOTECAN SUCROSOFATE SALT IN A PEGYLATED LIPOSOME, SUCH AS A LIPOSOME COMPRISING 1,2-DISTEAROYL-SN-PHOSPHATIDYLCHOLINE, CHOLESTEROL AND N-(OMEGA-METHOXY-POLY(ETHYLENE GLYCOL)...; REG. NO/DATE: EU/1 /16/1130 20161018
1746976 2017C/027 Belgium See Plans and Pricing PRODUCT NAME: LE SEL DE SUCROSOFATE D'IRINOTECAN, PAR EXEMPLE LE SEL DE SUCROSOFATE D'IRINOTECAN INCORPORE DANS UN LIPOSOME MODIFIE PAR PEGYLATION, TEL QU'UN LIPOSOME COMPRENANT DE LA 1,2-DISTEAROYL-SN- PHOSPHATIDYLCHOLINE, DU CHOLESTEROL ET DU N- (OMEGA-METHOXY POLY (ETHYLENE GLYCOL) (POIDS MOLECULAIRE 2000) -OXYCARBONYL)-1,2-DISEEAROYLPHOSPHATIDYLETHANOLAMINE, PAR EXEMPLE DANS DES RAPPORTS MOLAIRES 3: 2: 0,015; OU COMME DEMANDE AUXILIAIRE, IRINOTECAN; AUTHORISATION NUMBER AND DATE: EU/1/16/1130 20161018
0050793 94C0009 Belgium See Plans and Pricing PRODUCT NAME: COLFOSCERIL PALMITAS (DIPALMITOYLPHOSPHATIDYLCHOLINE) (DPPC); NAT REG.: 251 IS 142 F 12; FIRST REG.: GB PL 0003/0283 19901214
1758590 300907 Netherlands See Plans and Pricing PRODUCT NAME: DEOXYCHOLINEZUUR NATRIUMZOUT
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Harvard Business School
Medtronic
Boehringer Ingelheim
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.